IRVINE, Calif., Dec. 7 Masimo (Nasdaq: MASI), the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low Perfusion pulse oximetry, announced today that Brookdale University Hospital and Medical Center in Brooklyn, New York, has completed its system-wide conversion to Masimo SET pulse oximetry technology. As part of its system-wide technology standardization, Brookdale has also installed first-ever continuous and noninvasive hemoglobin monitoring (SpHb(TM)) technology in select care settings -- allowing clinicians to detect and treat chronic or acute anemia earlier, identify internal bleeding sooner, and more effectively manage blood transfusions for their patients.
By converting to Masimo SET, Brookdale clinicians gain all the Measure-Through Motion and Low Perfusion benefits of Masimo SET pulse oximetry, along with the breakthrough noninvasive blood constituent monitoring capabilities of Masimo Rainbow SET Pulse CO-Oximetry. Masimo Rainbow SET is the first-and-only technology platform capable of continuously and noninvasively measuring multiple blood constituents that previously required invasive procedures, including: total hemoglobin (SpHb(TM)), oxygen content (SpOC(TM)), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and PVI®, in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI). The ability to immediately detect and treat potentially life-threatening conditions -- without having to draw blood and wait for the results -- enables earlier and better clinical decisions that may help save lives and improve patient outcomes.
According to Thomas Crimi, M.D., Director of the Blood Conservation Program at Brookdale, Masimo SpHb is helping to improve blood management and conservation at Brookdale. "SpHb provides us with the unique ability to proactively identify and address patient's requiring blood transfusions much earlier, while avoiding unnecessary transfusions and other invasive tests. This certainly contributes to better quality care, patient safety, and improved clinical outcomes."
Masimo Founder and CEO, Joe E. Kiani, stated, "Brookdale's history of implementing sophisticated diagnostics and treatment technologies makes it the ideal care setting to pioneer Masimo SpHb for Brooklyn-area residents. We applaud their use of advanced medical technologies to help improve blood conservation efforts, patient care and clinical outcomes within their community."
The Brookdale University Hospital and Medical Center is one of Brooklyn's largest voluntary nonprofit teaching hospitals with 530 inpatient beds. With an extensive ambulatory care network, and an Emergency Department and Level I Trauma Center that is among the busiest in the region, Brookdale is also a New York State DOH designated Stroke Center.
Masimo (Nasdaq: MASI) develops innovative monitoring technologies that significantly improve patient care -- helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET® Pulse CO-Oximetry(TM), a breakthrough noninvasive blood constituent monitoring platform that can measure many blood constituents that previously required invasive procedures. Masimo Rainbow SET continuously and noninvasively measures total hemoglobin (SpHb(TM)), oxygen content (SpOC(TM)), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and PVI®, and acoustic respiration rate (RRa), in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early detection and treatment of potentially life-threatening conditions. Founded in 1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results, risks related to our belief that Masimo SET and Masimo Rainbow SET will provide sufficient sensitivity and specificity to detect physiological abnormalities in real-time, enabling clinicians to detect and identify potentially life-threatening conditions earlier and make better clinical and treatment decisions for their patients, risks related to our assumption that Masimo SET and Masimo Rainbow SET will deliver a sufficient level of clinical improvement over alternative pulse oximetry and noninvasive patient monitoring technologies to allow for further adoption of the technology at other hospitals, and risks related to our assumption that the conversion of Brookdale University Medical Center will serve to substantially increase revenues, as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these forward-looking statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
Masimo, SET, Signal Extraction Technology, Improving Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, RRa, Radical-7, Rad-87, Rad-57, Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are trademarks or registered trademarks of Masimo Corporation.
Media Contacts:Dana Banks Ruth RichmanMasimo Corporation Brookdale University Hospital(949) 297-7348 (718) email@example.com firstname.lastname@example.org